药师干预对缺血性脑血管疾病患者疗效及用药依从性的影响
|
摘要
目的探讨分析临床药师干预对缺血性脑血管疾病患者疗效及用药依从性的影响。方法选取解放军第一八○医院收治的80例缺血性脑血管疾病患者作为研究对象,将患者随机分为对照组40例和观察组40例,观察组在对照组治疗基础上采用临床干预措施,指导患者科学、合理、正确用药,比较2组患者的临床疗效、神经功能缺损(NIHSS)评分、生活自理能力评价量表(ADL)评分、认知功能量表(MMSE)和用药依从性。结果观察组患者的临床疗效和用药依从性明显优于对照组(P <0. 05); NIHSS评分低于对照组,ADL评分和MMSE评分高于对照组(P <0. 05)。对照组总有效率为80. 0%,观察组总有效率为92. 5%,差异有统计学意义(P <0. 05)。结论药师干预可显著改善缺血性脑血管疾病的临床疗效和用药依从性,改善患者的临床症状,降低用药风险,值得临床推广使用。
Objective To investigate the effects of clinical pharmacist intervention on efficacy of the patients with ischemic cerebrovascular disease and medication compliance. Methods Eighty patients with ischemic cerebrovascular disease treated in No. 180 Hospital of the People's Liberation Army were recruited as study subjects and were randomly divided into the control group and the treatment group,each consisting of 40 patients. The patients of the treatment group was intervened with intervention measures in addition to the drug therapy as received by the patients of the control group,i. e. they were instructed by clinical pharmacists in safe,rational and correct use of drugs. Then,clinical therapeutic efficacy,neurologic impairment( NIHSS) scores,the activities of daily life( ADL),mini-mental state examination( MMSE) scores and medication compliance were compared between the patients of the 2 groups. Results The therapeutic efficacy and medication compliance in the patients of the observation group were obviously superior to those of the control group( P < 0. 05),NIHSS scores of the observation group were lower than those of the control group( P < 0. 05),and the ADL and MMSE scores were higher than those of the control group( P < 0. 05). Total effective rate of the control group was 80. 0%,while that of observation group was 92. 5%,with statistical significance( P < 0. 05). Conclusion Clinical pharmacist intervention could significantly improve the therapeutic efficacy and medication compliance,as well as clinical symptoms,and reduce medication risks in patients with ischemic cerebrovascular disease. For this reason,it is worthy further clinical extension.
Objective To investigate the effects of clinical pharmacist intervention on efficacy of the patients with ischemic cerebrovascular disease and medication compliance. Methods Eighty patients with ischemic cerebrovascular disease treated in No. 180 Hospital of the People's Liberation Army were recruited as study subjects and were randomly divided into the control group and the treatment group,each consisting of 40 patients. The patients of the treatment group was intervened with intervention measures in addition to the drug therapy as received by the patients of the control group,i. e. they were instructed by clinical pharmacists in safe,rational and correct use of drugs. Then,clinical therapeutic efficacy,neurologic impairment( NIHSS) scores,the activities of daily life( ADL),mini-mental state examination( MMSE) scores and medication compliance were compared between the patients of the 2 groups. Results The therapeutic efficacy and medication compliance in the patients of the observation group were obviously superior to those of the control group( P < 0. 05),NIHSS scores of the observation group were lower than those of the control group( P < 0. 05),and the ADL and MMSE scores were higher than those of the control group( P < 0. 05). Total effective rate of the control group was 80. 0%,while that of observation group was 92. 5%,with statistical significance( P < 0. 05). Conclusion Clinical pharmacist intervention could significantly improve the therapeutic efficacy and medication compliance,as well as clinical symptoms,and reduce medication risks in patients with ischemic cerebrovascular disease. For this reason,it is worthy further clinical extension.
引文
[1]张振强,宋军营,贾亚泉.缺血性脑血管疾病研究进展[J].河南大学学报(医学版),2012,31(4):312-317. DOI:10. 15991/j. cnki. 41-1361/r. 2012. 04. 010.
[2]游然,幸敏丽,沈海涛,等.缺血性脑血管疾病的发病机制及治疗药物[J].药学进展,2009,33(6):247-253. DOI:10. 3969/j. issn. 1001-5094. 2009. 06. 002.
[3] 5 The European Stroke Organisation(ESO)Ex-exeutive Committee and the ESO Writing Committee. Guidelines for management of isehemie stroke and TIA 2008[J]. Cerebrovaseular Deseas,2008,25(5):457-507. DOI:10. 1159/000131083.
[4]脑卒中患者临床神经功能缺损程度评分标准(1995)[J].中华神经科杂志,1996,29(6):381-382.
[5]李宗敏,孟继民,胡荣,等.血栓通注射剂治疗脑梗死临床观察[J].湖北中医杂志,2013,35(9):38-39. DOI:10. 3969/j.issn. 1000-0704. 2013. 09. 021.
[6]和慧秋.注射用血塞通与血栓通治疗心脑血管疾病的不良反应比较[J].内蒙古中医药,2014,33(27):89-90. DOI:10.16040/j. cnki. cn15-1101. 2014. 27. 284.
[7] Shiino A,Akiguchi I,Watanabe T,et al. Morphometric characterization of binswanger's disease:comparison with alzheimer's disease[J]. Europ J Radiol,2012,81(9):2375-2379. DOI:10.1016/j. ejrad. 2011. 05. 031.
[8]乐欢.血栓通治疗缺血性脑血管疾病的临床疗效[J].临床合理用药,2017,10(8C):43-44. DOI:10. 15887/j. cnki. 13-1389/r. 2017. 24. 021.
[9]陈宗胜.缺血性脑血管病介入诊断及治疗进展[J].中西医结合心血管病杂志,2014(4):173-174.
[10]郑广长.我院2005年度门诊不合理用药分析[J].中国药事,2007,21(9):778. DOI:10. 3969/j. issn. 1002-7777. 2007. 09. 045.
[11]陶霞,钟泽清,陶德平,等.慢性疾病老干部患者不规范用药相关因素的调查分析[J].护理管理杂志,2007,7(12):14.
[12]杨旭权.临床不合理用药分析及对策[J].中国当代医药,2010,17(20):151. DOI:10. 3969/j. issn. 1674-4721. 2010. 20. 093.
[13]谭森,易多奇.临床药师对临床不合理用药的药学干预分析[J].寻医问药,2012,10(2):259-260.
[14]赵薇,任常顺,王帅.临床不合理用药的原因及干预因素[J].中国当代医药,2013,20(2):18-19. DOI:10. 3969/j. issn.1674-4721. 2013. 02. 008.
[2]游然,幸敏丽,沈海涛,等.缺血性脑血管疾病的发病机制及治疗药物[J].药学进展,2009,33(6):247-253. DOI:10. 3969/j. issn. 1001-5094. 2009. 06. 002.
[3] 5 The European Stroke Organisation(ESO)Ex-exeutive Committee and the ESO Writing Committee. Guidelines for management of isehemie stroke and TIA 2008[J]. Cerebrovaseular Deseas,2008,25(5):457-507. DOI:10. 1159/000131083.
[4]脑卒中患者临床神经功能缺损程度评分标准(1995)[J].中华神经科杂志,1996,29(6):381-382.
[5]李宗敏,孟继民,胡荣,等.血栓通注射剂治疗脑梗死临床观察[J].湖北中医杂志,2013,35(9):38-39. DOI:10. 3969/j.issn. 1000-0704. 2013. 09. 021.
[6]和慧秋.注射用血塞通与血栓通治疗心脑血管疾病的不良反应比较[J].内蒙古中医药,2014,33(27):89-90. DOI:10.16040/j. cnki. cn15-1101. 2014. 27. 284.
[7] Shiino A,Akiguchi I,Watanabe T,et al. Morphometric characterization of binswanger's disease:comparison with alzheimer's disease[J]. Europ J Radiol,2012,81(9):2375-2379. DOI:10.1016/j. ejrad. 2011. 05. 031.
[8]乐欢.血栓通治疗缺血性脑血管疾病的临床疗效[J].临床合理用药,2017,10(8C):43-44. DOI:10. 15887/j. cnki. 13-1389/r. 2017. 24. 021.
[9]陈宗胜.缺血性脑血管病介入诊断及治疗进展[J].中西医结合心血管病杂志,2014(4):173-174.
[10]郑广长.我院2005年度门诊不合理用药分析[J].中国药事,2007,21(9):778. DOI:10. 3969/j. issn. 1002-7777. 2007. 09. 045.
[11]陶霞,钟泽清,陶德平,等.慢性疾病老干部患者不规范用药相关因素的调查分析[J].护理管理杂志,2007,7(12):14.
[12]杨旭权.临床不合理用药分析及对策[J].中国当代医药,2010,17(20):151. DOI:10. 3969/j. issn. 1674-4721. 2010. 20. 093.
[13]谭森,易多奇.临床药师对临床不合理用药的药学干预分析[J].寻医问药,2012,10(2):259-260.
[14]赵薇,任常顺,王帅.临床不合理用药的原因及干预因素[J].中国当代医药,2013,20(2):18-19. DOI:10. 3969/j. issn.1674-4721. 2013. 02. 008.